CLINICAL TRIALS PROFILE FOR PHEXXI
✉ Email this page to a colleague
All Clinical Trials for phexxi
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT01306331 ↗ | Study of Contraceptive Efficacy & Safety of Phexxi™ (Previously Known as Amphora) Gel Compared to Conceptrol Vaginal Gel | Completed | Health Decisions | Phase 3 | 2011-04-01 | This is a research study of a new experimental vaginal gel that helps in vaginal pH regulation and results in immobilization of spermatozoa by maintaining the normally low vaginal pH, even in the presence of semen. This vaginal gel is called Phexxi™ (previously known as Amphora) and was compared to a commercially available spermicide called Conceptrol®, which contains nonoxynol 9; commonly abbreviated as N-9. Conceptrol® can help prevent pregnancy. This study objective was to determine if this product prevents pregnancy when inserted into the vagina before intercourse. |
| NCT01306331 ↗ | Study of Contraceptive Efficacy & Safety of Phexxi™ (Previously Known as Amphora) Gel Compared to Conceptrol Vaginal Gel | Completed | Evofem Inc. | Phase 3 | 2011-04-01 | This is a research study of a new experimental vaginal gel that helps in vaginal pH regulation and results in immobilization of spermatozoa by maintaining the normally low vaginal pH, even in the presence of semen. This vaginal gel is called Phexxi™ (previously known as Amphora) and was compared to a commercially available spermicide called Conceptrol®, which contains nonoxynol 9; commonly abbreviated as N-9. Conceptrol® can help prevent pregnancy. This study objective was to determine if this product prevents pregnancy when inserted into the vagina before intercourse. |
| NCT03243305 ↗ | AMP002 Phase III Contraceptive Study | Completed | Parexel | Phase 3 | 2017-07-24 | This is a single-arm, open-label, Phase III study in approximately 100 sites in the United States (US) over seven cycles of use in women aged 18 to 35 years who are at risk of pregnancy. |
| NCT03243305 ↗ | AMP002 Phase III Contraceptive Study | Completed | Evofem Inc. | Phase 3 | 2017-07-24 | This is a single-arm, open-label, Phase III study in approximately 100 sites in the United States (US) over seven cycles of use in women aged 18 to 35 years who are at risk of pregnancy. |
| NCT05753813 ↗ | Exploring the Effects of an Intravaginal Lactic Acid Gel on the Vaginal Microbiome | Recruiting | University of Hawaii Foundation | Early Phase 1 | 2023-02-27 | This project aims to investigate if the contraceptive method, Phexxi, causes changes to the composition of the vaginal microbiome. The investigators hypothesize that regular use of Phexxi will cause increased colonization of lactic acid-producing lactobacilli, which could have positive effects in the way of preventing recurrent episodes of BV and candida infections. |
| NCT05753813 ↗ | Exploring the Effects of an Intravaginal Lactic Acid Gel on the Vaginal Microbiome | Recruiting | Queen's Medical Center | Early Phase 1 | 2023-02-27 | This project aims to investigate if the contraceptive method, Phexxi, causes changes to the composition of the vaginal microbiome. The investigators hypothesize that regular use of Phexxi will cause increased colonization of lactic acid-producing lactobacilli, which could have positive effects in the way of preventing recurrent episodes of BV and candida infections. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for phexxi
Condition Name
Clinical Trial Locations for phexxi
Trials by Country
Clinical Trial Progress for phexxi
Clinical Trial Phase
Clinical Trial Sponsors for phexxi
Sponsor Name
